IIM
OVID icon

INTECH Investment Management’s Ovid Therapeutics OVID Stock Holding History

INTECH Investment Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-44,010
Closed -$13.7K – 2612
2025
Q1 		$13.7K Buy
44,010
+20,286
+86% +$12.5K ﹤0.01% 2512
2024
Q4 		$22.2K Buy
+23,724
New +$26.5K ﹤0.01% 2370

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

INTECH Investment Management's OVID Position: Q2 2025 in Review

INTECH Investment Management sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 44,010 shares — an estimated $13.7K sold.

INTECH Investment Management first reported a position in OVID in Q4 2024 and held it in 2 quarters. The position peaked at $22.2K in Q4 2024. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

  • INTECH Investment Management reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
  • INTECH Investment Management sold 44,010 Ovid Therapeutics shares in Q2 2025, an estimated $13.7K.
  • INTECH Investment Management first reported a position in Ovid Therapeutics in Q4 2024 and held it in 2 quarters.
  • INTECH Investment Management's Ovid Therapeutics position peaked at $22.2K in Q4 2024.
  • 71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on INTECH Investment Management's 13F filing for Q2 2025, filed 8 Aug 2025.